Enhance Skin Products Inc. is a developer of premium cosmeceutical products marketed under its Visible Youth™ trademark. Cosmeceuticals are EHSK (Enhance Skin Products, Inc.) functions as a holding company owning 17.87% of the shares of Integumen. Integumen is focused on skin, oral
topically applied products containing ingredients that influence the biological function of skin and can be described as a marriage between cosmetics and
pharmaceuticals. These products may improve the appearance and condition of the skin by delivering nutrients or protectants necessary for healthy skin.
and wound care products. They have also developed a synthetic human skin equivalent with the stated purpose of eliminating the need for live test subjects in product testing.
Enhance Skin Products, Inc.
2033 Gateway Place
San Jose, CA 95110
TIMELINE OF EVENTS RELATED TO INTEGUMEN AND RELATIONSHIP WITH ENHANCE SKIN PRODUCTS
April 5, 2017: Integumen Shares Begin Trading on London Stock Exchange (AIM:SKIN)
October 26, 2016: Integumen Website Goes Live
October 26, 2016: Venn Life Sciences Shareholders Approve Sale of Innovenn to Integumen
October 5, 2016: Tony Richardson Speaks About Spinning Innovenn Off Into Integumen (EHSK will own an estimated 24% stake in Integumen)
October 5, 2016: 8K Filed Officially Documenting the Deal With Integumen
October 4, 2016: Enhance Skin Products Inc. Announces a Strategic Collaboration With Integumen Limited and Asset Sale
August 15, 2016: Biosurface Limited applies to change name to Integumen Limited
July 7, 2016: Biosurface Limited and EHSK enter into option agreement
May 28, 2016: Biosurface Limited formed
The players involved in this deal are HUGE.
"Integumen is a personal health company developing
and commercialising technology and products for the
human integumentary system that may improve physical
appearance, hygiene and general health outcomes."
Integumen is a personal health company developing and commercialising technology and products for the
human integumentary system that may improve physical appearance, hygiene and general health outcomes.
The integumentary system is the surfaces and barriers of the human body, largely
comprised of the skin. Integumen has a portfolio of products and technologies
which broadly focus on applications with identified and growing markets within skincare, oral care
and wound care which are either on the market or at an advanced stage of product development.
The Company is organised into four divisions:
Meet the Team
Chief Financial Officer & Interim Chief Executive Officer
Chris joined Integumen in September 2016 with over 25 years’ of experience in mergers and acquisitions, fundraisings and business process design. Prior to
joining Integumen in 2016, Chris was Chief Financial Officer of Greenstar, one of Ireland’s largest recycling and waste-to-energy companies, with a turnover of
€98 million and employing 675 staff. Previously, Chris held a number of senior finance positions in manufacturing, design and engineering companies within a
range of private equity, PLC and owner-manager environments,. Chris is a Fellow of Chartered Accountants Ireland, having qualified with Pannell Kerr Forster in 1989.
Tony Richardson is CEO of Venn Life Sciences. He has over 16 years’ experience in the Life Science arena. Mr. Richardson has held key leadership
positions in a number of Medical Technology companies and has accumulated considerable transaction experience including IPO, financings and M&A.